A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma

J Clin Pharmacol. 1976 Aug-Sep;16(8-9):433-8. doi: 10.1002/j.1552-4604.1976.tb02418.x.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Clinical Trials as Topic
  • Female
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Piperazines / therapeutic use*
  • Razoxane / adverse effects
  • Razoxane / pharmacology
  • Razoxane / therapeutic use*

Substances

  • Immunosuppressive Agents
  • Piperazines
  • Razoxane